Oxycodone/Naloxone Nordic Drugs (Oxycodone Hydrochloride, Naloxone Hydrochloride Dihydrate)

Oxycodone Hydrochloride, the active ingredient in Oxycodone/Naloxone Nordic Drugs, is an opioid analgesic presented as a combination tablet for oral use. It treats moderate to severe pain in adult patients when an opioid analgesic is required. GNH USA supplies Oxycodone/Naloxone Nordic Drugs as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Oxycodone/Naloxone Nordic Drugs as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Oxycodone/Naloxone is used primarily for pain management within the opioid pathway.

- Chronic non‑cancer pain: provides opioid analgesia while reducing opioid‑induced constipation. - Cancer‑related pain: delivers strong pain relief in patients with advanced disease. - Post‑operative pain: controls acute pain after major surgery when rapid, effective analgesia is needed. - Severe musculoskeletal pain: alleviates intense pain from conditions such as severe osteoarthritis or rheumatoid arthritis. - Pain associated with palliative care: improves comfort in end‑of‑life settings.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea and vomiting: mild to moderate gastrointestinal upset. - Constipation: reduced bowel motility despite naloxone's protective effect. - Dizziness or light‑headedness: transient sensation of unsteadiness. - Drowsiness or somnolence: increased sleepiness, especially after dose initiation. - Dry mouth: reduced salivary flow causing oral discomfort. - Pruritus: mild itching, often localized.

Serious or Rare Side Effects: - Respiratory depression: slowed breathing that can be life‑threatening. - Severe hypotension: marked drop in blood pressure leading to fainting. - Opioid dependence or addiction: risk of misuse with prolonged therapy. - Hepatic impairment: elevated liver enzymes indicating liver stress. - Allergic reactions: rash, swelling, or anaphylaxis in susceptible individuals. - Withdrawal symptoms: abrupt discontinuation may trigger opioid withdrawal signs.

When prescribing Oxycodone/Naloxone, clinicians should consider several safety measures.

- Assess pain severity: confirm that opioid therapy is appropriate for the patient’s level of pain. - Evaluate gastrointestinal risk: monitor for constipation despite naloxone’s protective role. - Screen for respiratory conditions: patients with COPD or sleep‑apnea need close observation. - Review medication history: avoid concurrent use with other central nervous system depressants. - Counsel on dependence: educate patients about the potential for addiction and proper use. - Store at ambient temperature: keep below 25°C in the original packaging, protected from moisture.

Oxycodone/Naloxone can interact with a range of medicines, requiring careful management.

Major Interactions (Avoid): - Benzodiazepines: combined CNS depression can cause profound respiratory depression. - MAO inhibitors: risk of severe serotonin syndrome and hypertensive crisis. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase oxycodone plasma levels, heightening toxicity.

Moderate Interactions (Monitor Closely): - CNS depressants (e.g., antihistamines, muscle relaxants): may enhance sedation and dizziness. - CYP2D6 inhibitors (e.g., fluoxetine): can alter oxycodone metabolism, affecting analgesic response. - Diuretics: may exacerbate hypotension when combined with opioid‑induced vasodilation.